山东医药
山東醫藥
산동의약
SHANDONG MEDICAL JOURNAL
2014年
42期
8-10
,共3页
冯红蕾%崔林%李泽%韩月婷%张鹏
馮紅蕾%崔林%李澤%韓月婷%張鵬
풍홍뢰%최림%리택%한월정%장붕
乳腺癌%D-二聚体%临床病理特征%预后
乳腺癌%D-二聚體%臨床病理特徵%預後
유선암%D-이취체%림상병리특정%예후
breast cancer%D-dimer%clinical pathologic characteristics%prognosis judgment
目的:分析不同临床病理特征的乳腺癌患者血浆D-二聚体( D-D)水平的差异,探讨血浆D-D检测在乳腺癌病情监测及预后判断中的应用价值。方法选择资料保存完整的乳腺癌患者189例,其中接受外科手术治疗者129例,接受全身辅助治疗者60例。所有患者经治疗6~8个月后复诊时,完全缓解(CR)53例、部分缓解(PR)47例、疾病稳定(SD)48例、疾病进展(PD)41例。分别于治疗前、治疗后14 d、治疗后6~8个月复诊时,采用酶联免疫荧光法检测静脉血血浆D-D水平。比较不同年龄、乳腺癌病理类型、TNM分期、肿瘤大小、淋巴结转移、雌激素受体( ER)表达、孕激素受体( PR)表达、人类表皮生长因子受体-2( HER-2)表达、手术治疗前后、全身辅助治疗前后及不同临床疗效( CR、PR、SD、PD)患者的血浆D-D水平。结果 TNM分期Ⅲ、Ⅳ期者血浆D-D水平高于Ⅰ、Ⅱ期患者,肿瘤直径≥5 cm者血浆D-D水平高于肿瘤直径<5 cm者,有淋巴结转移者血浆D-D水平高于未转移者,手术治疗后血浆D-D水平低于治疗前,全身辅助治疗后血浆D-D水平低于治疗前( P均<0.05)。临床疗效为CR、PR者治疗后血浆D-D水平低于治疗前,PD者治疗后血浆D-D水平高于治疗前(P均<0.05),SD者治疗前后血浆D-D水平差异无统计学意义。结论血浆D-D水平与乳腺癌患者的TNM分期、肿瘤直径、淋巴结转移及预后有关,手术及全身辅助治疗可降低血浆D-D水平。
目的:分析不同臨床病理特徵的乳腺癌患者血漿D-二聚體( D-D)水平的差異,探討血漿D-D檢測在乳腺癌病情鑑測及預後判斷中的應用價值。方法選擇資料保存完整的乳腺癌患者189例,其中接受外科手術治療者129例,接受全身輔助治療者60例。所有患者經治療6~8箇月後複診時,完全緩解(CR)53例、部分緩解(PR)47例、疾病穩定(SD)48例、疾病進展(PD)41例。分彆于治療前、治療後14 d、治療後6~8箇月複診時,採用酶聯免疫熒光法檢測靜脈血血漿D-D水平。比較不同年齡、乳腺癌病理類型、TNM分期、腫瘤大小、淋巴結轉移、雌激素受體( ER)錶達、孕激素受體( PR)錶達、人類錶皮生長因子受體-2( HER-2)錶達、手術治療前後、全身輔助治療前後及不同臨床療效( CR、PR、SD、PD)患者的血漿D-D水平。結果 TNM分期Ⅲ、Ⅳ期者血漿D-D水平高于Ⅰ、Ⅱ期患者,腫瘤直徑≥5 cm者血漿D-D水平高于腫瘤直徑<5 cm者,有淋巴結轉移者血漿D-D水平高于未轉移者,手術治療後血漿D-D水平低于治療前,全身輔助治療後血漿D-D水平低于治療前( P均<0.05)。臨床療效為CR、PR者治療後血漿D-D水平低于治療前,PD者治療後血漿D-D水平高于治療前(P均<0.05),SD者治療前後血漿D-D水平差異無統計學意義。結論血漿D-D水平與乳腺癌患者的TNM分期、腫瘤直徑、淋巴結轉移及預後有關,手術及全身輔助治療可降低血漿D-D水平。
목적:분석불동림상병리특정적유선암환자혈장D-이취체( D-D)수평적차이,탐토혈장D-D검측재유선암병정감측급예후판단중적응용개치。방법선택자료보존완정적유선암환자189례,기중접수외과수술치료자129례,접수전신보조치료자60례。소유환자경치료6~8개월후복진시,완전완해(CR)53례、부분완해(PR)47례、질병은정(SD)48례、질병진전(PD)41례。분별우치료전、치료후14 d、치료후6~8개월복진시,채용매련면역형광법검측정맥혈혈장D-D수평。비교불동년령、유선암병리류형、TNM분기、종류대소、림파결전이、자격소수체( ER)표체、잉격소수체( PR)표체、인류표피생장인자수체-2( HER-2)표체、수술치료전후、전신보조치료전후급불동림상료효( CR、PR、SD、PD)환자적혈장D-D수평。결과 TNM분기Ⅲ、Ⅳ기자혈장D-D수평고우Ⅰ、Ⅱ기환자,종류직경≥5 cm자혈장D-D수평고우종류직경<5 cm자,유림파결전이자혈장D-D수평고우미전이자,수술치료후혈장D-D수평저우치료전,전신보조치료후혈장D-D수평저우치료전( P균<0.05)。림상료효위CR、PR자치료후혈장D-D수평저우치료전,PD자치료후혈장D-D수평고우치료전(P균<0.05),SD자치료전후혈장D-D수평차이무통계학의의。결론혈장D-D수평여유선암환자적TNM분기、종류직경、림파결전이급예후유관,수술급전신보조치료가강저혈장D-D수평。
Objective To analyze the correlation between the serum level of D-D and clinicopathologic feature of breast cancer patients, to investigate the clinical value of D-D in therapeutic effect monitoring and prognosis judgement of breast cancer.Methods A total of 189 breast cancer patients were involved in this study, including 129 surgery patients and 60 systemic chemotherapy patients.After a recertification of 6 to 8 months later, the curative effects were collected as 53 cases of complete remission( CR) , 47 cases of partial remission( PR) , 48 cases of stable disease( SD) and 41 cases of progressive disease( PD) .The serum D-D level of all patients were detected by ELISA method at the time of treatment be-fore, 14 days after treatment and 6 to 8 months recertification.The correlation between the serum level of D-D and age, pathological type, TNM-stage, tumor size, lymph node metastasis, surgical treatment, systemic therapy, ER expression, PR expression, HER-2 expression, clinical prognosis of breast cancer were analyzed .Results The serum level of D-D inⅢ, Ⅳstage, tumor size≥5 cm, lymph node metastasis, surgery treatment, systemic chemotherapy were significant higher (P<0.05).The post treatment serum level of D-D in CR, PR patients were significant lower than treatment before (P<0.05).The post treatment serum level of D-D in PD patients were significant higher than treatment before (P<0.05). The serum level of D-D in SD patients showed no significant difference before and post treatment.Conclusions The serum level of D-D in breast cancer was positively correlated with the clinical pathologic characteristics such as TNM-stage, tumor size, lymph node metastasis and prognoses.The serum level of D-D level in breast cancer patients decreased after surgery and systemic treatment.